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3. Abbreviations 
 
BIA  Bio-electrical impedance analysis  
BMD  Bone mineral density 
CCR   Conventional chest X-ray  
CFCS  Cystic Fibrosis Clinical Score 
CFRDM CF-related diabetes mellitus 
CFTR  Cystic-fibrosis-transmembrane-conductance-regulator 
DEXA  Dual-energy X-ray absorptiometry 
DHA  Docosahexaenoic acid (omega-3 fatty acid) 
DIOS  Distal intestinal obstruction syndrome 
EFA  Essential fatty acids 
EPA  Eicosapentaenoic acid (omega-3 fatty acid) 
GER  Gastroesofageal reflux 
FE-1  (Human) Faecal elastase-1 
FEV1  Forced expiratory volume in one second (percent of predicted) 
FVC  Forced vital capacity (percent of predicted) 
HRCT  High-resolution computer tomography 
IC  Indirect calorimetry 
MBW  Multiple breath inert gas washout  
NIH score National Institutes of Health score 
PEG  Percutaneous endoscopic gastrostomy  
PFT  Pulmonary function tests 
PI  Exocrine pancreatic insufficiency 
PS  Sufficient exocrine pancreatic function 
PSA  Pseudomonas aeruginosa 
REE  Resting energy expenditure (percent of predicted) 
SK score Shwachman-Kulczycki score  
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4.  Introduction 
 
 
4.1 Background 
 
Cystic fibrosis (CF) is the most common life-limiting autosomal-recessive disease in 
Caucasians with a prevalence of 1:2500 - 3500 living birth in most European 
countries and the United States (1;2). Approximately 250 patients with CF are living 
in Norway today and 50% are older than 18 years.  
 
CF was distinguished from celiac disease and recognised as an own entity in 1938 
(3). DiSant' Agnese and colleagues identified elevated sweat chloride and sodium 
concentrations to be the major tool in diagnosing CF in the early fifties, and since 
then, the sweat iontophoresis has been a cornerstone of diagnosis (4). Successful 
identification of the CF gene was accomplished in 1989 and localised on 
chromosome 7 (5-7). The CF gene encodes a large, single-chain protein that forms a 
membrane bound chloride channel, the cystic-fibrosis-transmembrane-conductance-
regulator (CFTR). More than 1200 different mutations have been found so far (8). 
However, approximately 70% of all CF patients are homozygous for the ∆F508-
mutation (9). Mutations of the CF gene can either result in reduced amount of CFTR 
protein, transport hindrance of the protein to the plasma membrane or chloride 
channel dysfunction (10). Although these mutations affect epithelial ion and water 
transport through cell membranes of exocrine organs, the phenotypic expression 
varies greatly. 
Basically, the impaired epithelial ion and water transport result in mucus of higher 
viscosity. This viscous mucus is accumulating in excretory ducts of the organs that 
express CFTR in particular, the respiratory, the gastrointestinal, the hepatobiliary and 
the reproductive tract. Mucus accumulation associated with progressive obstruction 
leads to subsequent destruction of these organs.  
Fatty diarrhoea and failure to thrive in combination with therapy resistant productive 
cough is characteristically prominent in children. The classic “diagnostic triad” 
consists of abnormal sweat chloride concentration (>60 mmol/L) and pulmonary and 
exocrine pancreatic disease. A sibling or first cousin with CF as well as identification 
of two CFTR mutations are other important indicators of CF (11). Transepithelial 
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nasal potential difference measurements are useful in assisting in the diagnosis of 
atypical CF; however, this diagnostic approach is not available in Norway. Recent 
reports indicate that computer tomography of the paranasal sinuses may give 
additional information in cases of diagnostic uncertainty (12;13). 
In the longer run repetitive bacterial lung infections, progressive bronchiectasis, 
decreasing alveolar gas exchange and malnutrition are responsible for high morbidity 
and mortality among CF patients (14-16). Early in life, patients with CF become 
infected with a limited spectrum of bacteria, where Pseudomonas aeruginosa (PSA) 
becomes the predominant organism (17). Once chronic (endobronchial) PSA lung 
infection is established, more rapid deterioration of lung function begins and 
continues until death. Moreover, CF-related diabetes mellitus (CFRDM) is a frequent 
complication of CF and is associated with declining pulmonary function and 
increased mortality (18;19). 
 
There is no cure of the primary defect yet. The major goal is controlling the 
heterogenic symptoms and preventing complications effectively in order to slow down 
or halt disease progression. Managing CF is complex and rather challenging for 
everyone involved; the family in particular, numerous medical staff, different 
authorities on community level, as well as personnel in Kindergarten and in school. 
Care of these patients demand almost constant supervision from their direct 
environment, but they need to be treated as normal children all the same.  
Regular airway clearance, treatment of lung infection and nutritional therapy are the 
cornerstones of CF care. Current therapies consist of mucolytic agents, numerous 
chest physiotherapy techniques, inhaled bronchodilators, antibiotics and nutrional 
therapy like high-fat/high-energy diet, supplementation of pancreatic enzymes and 
essential nutrient supplementation. Aggressive treatment regimes and close patients’ 
surveillance have contributed to improved life quality and expectancy the last 
decades. The median life expectancy has improved dramatically from six month in 
1940, to 18 years in 1976 and to over 30 years these days (20) and is continuously 
improving. However, gene therapy, as the ultimate solution that addresses the 
primary chloride channel defect directly, still remains a challenge for the future. 
 10 
 
4.2 Surveillance of lung disease 
 
Chronic pulmonary disease is the major cause of morbidity in the majority of patients 
and more than 90% of all deaths in CF are related to pulmonary disease. Therefore, 
early detection of damage to the lung parenchyma is of major interest in the 
management of CF. Traditionally, conventional chest X-ray (CCR) and pulmonary 
function tests (PFT) play an important role in the follow-up of these patients. 
Hyperinflation of the lungs and airway obstruction increase as the disease 
progresses, and forced expiratory volume in one second (FEV1) is widely used both 
as follow-up and prognostic factor (21). 
Recently, pulmonary high-resolution computed tomography (HRCT) has been 
advocated as a precise diagnostic method, which gives the opportunity to detect 
even slight disease progression. HRCT visualises the airway involvement 
characteristically and makes this procedure superior to CCR for diagnosis and follow-
up of patients with CF (22-24). Different systematic HRCT scores have been 
proposed to classify these findings, of which Bhalla's is the most commonly used 
(25). HRCT scans confer detailed information of the distribution and severity of CF 
specific airway and lung parenchymal disease (26;27) and scoring of the pathological 
findings carry the opportunity to quantify structural lung damage. Moreover, there are 
promising reports of composite HRCT/PFT scores and quantitative air trapping 
measurements to be more sensitive in discriminating early or mild CF lung disease 
(28;29). Lately, multiple breath inert gas washout (MBW) has been advocated as a 
promising method to evaluate ventilation maldistribution. Using MBW, the sensitivity 
to detect early CF lung disease in children with CF was higher than traditional 
spirometry (30-32).  
However, the benefit of HRCT examinations has to be weighed up against the 
radiation dosage when performing HRCT-examinations. Therefore, the decision for 
pulmonary HRCT scans should be taken for each patient individually when used 
beyond scientific research. 
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4.3 Clinical scoring of disease severity 
 
Categorization of clinical scoring has contributed to the success of clinical trials and 
helped towards a better understanding of this heterogeneous and complex disease. 
Scoring systems have reduced intuitive subjective assessments and provided a 
means of quantifying the rate of decline in clinical status (33). Scores have been 
widely adopted in attempts to standardize recordings of the diverse manifestations of 
CF in order to alert to any subtle deviation from clinical stability.  
There are a number of clinical scoring systems, of which perhaps the best known is 
the Shwachman score (34). Shwachman and Kulczycki invented this score as early 
as in 1958, with general activity, physical findings, nutritional status and CCR as main 
categories. The assessment is semi-quantitative and allows a simple, however rough 
orientation of the patients general condition (excellent, good, mild, moderate, severe). 
Other clinical scores like the Doershuk score (35), the Cooperman score (36), the 
NIH score, also known as Taussig score (37) or the CFCS (38) are considered as 
more advanced and modern clinical scores compared to the original SK score. 
Moreover, there are numerous scores, which are based on chest radiograph scores 
alone, like the Chrispin-Norman score (39), Berner score (40), Brasfield score (41), 
Wisconsin score (42) and the Northern score (43), and there is still an ongoing 
debate which of these scores is the most appropriate method to evaluate the clinical 
condition (44).  
However, despite this great variety of scoring alternatives and several limitations of 
the SK score itself, the SK score is still the most used clinical score to assess and 
monitor over-all disease severity in patients with CF. Nevertheless, scoring does not 
necessarily reflect the reality in this complex disease and scores in general have to 
be used with an awareness of their limitations. 
Clinical scoring is no substitute for close clinical appraisal and adequate 
interpretation of pulmonary function tests and chest imaging methods. 
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4.4 Energy deficiency 
 
Patients with CF are at high risk for malnutrition, which may result in accelerated 
progression of the disease and increased morbidity. Therefore, optimal nutrition is an 
integral part of CF care. Long term follow-up of CF patients has shown significantly 
better survival in those who achieved normal nutritional status (45;46). During the last 
20 years, it has become increasingly clear that nutritional status has an impact on 
lung disease and lung function in CF patients (47-52). Recently, Peterson and 
colleagues found that children who weigh more and who gain weight at an 
appropriate and uninterrupted rate have a better FEV1 outcome (53).  
In addition to increased energy losses secondary to the exocrine pancreatic 
insufficiency, factors like inappropriate energy intake or elevated resting energy 
expenditure (REE, basal metabolism) contribute to energy imbalance in CF. 
Generally, REE accounts for 60-75% of total energy expenditure in humans, leaving 
10-25% to physical activity and 10% for diet-induced thermogenesis (54). REE itself 
can be raised like in CF, leading to higher energy consumption and thus contribute to 
deterioration of the nutritional status. Respiratory tract inflammation and bacterial 
lung infection are considered to be the most important factors which contribute to 
elevated REE in CF. 
Schöni and colleagues (55) developed a model to describe the progressive lung 
destruction in people with CF (Figure 1). Increased cardiac output due to a fixed 
pulmonary capillary bed and raised work of breathing reflect a hypermetabolic state 
which results in respiratory muscle fatigue. Shorter time to recover for respiratory 
muscles is a consequence of hyperinflation, and leads itself to diaphragm fatigue. 
Malnutrition on the other hand results in loss of muscle mass of the respiratory 
muscles.  
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Figure 1: The destructive circle in CF (mod. Schöni 2000) 
 
 
 
Therefore, Schöni and co-workers pointed out weight loss and lung damage as 
crucial components in the pathogenesis of CF lung destruction. Focus of intervention 
should concentrate on both components as early as possible. Oral nutritional 
supplementation, feeding through enteral tube or percutaneous endoscopic 
gastrostomy (PEG) are options that characterize modern, offensive nutritional 
therapy (56), and they have to be taken into consideration when decrease or any halt 
in weight gain is present. 
Loss of weight 
Loss of 
respiratory 
muscles  
Lung damage 
from underlying 
disease 
Increased 
work of 
breathing 
Hyperinflation
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4.5 Faecal elastase-1 (FE-1) and fat-soluble vitamins 
 
Steatorrhea is common in patients with CF and reflects a clinical manifestation of 
maldigestion and malabsorption. By late childhood, up to 90% of all patients have 
developed exocrine pancreatic insufficiency (PI), which results in massive faecal 
energy loss and therefore deteriorates nutritional status and energy balance (57). 
The assessment of maldigestion in patients with CF can be performed by measuring 
(human) faecal elastase-1. This is a simple, reliable and non-invasive test to evaluate 
exocrine pancreatic function (58-61). Results are not influenced by enzyme 
supplementation, and this method is characterized by high sensitivity (>90%) and 
specificity (99%).  
Pancreatic insufficiency, variable degrees of bile salt disturbance and hepatobiliary 
dysfunction make fat-soluble vitamin deficiency common in CF. Profiles of vitamins A 
(retinol), D (25-hydroxyvitamin D) and E (alpha-tocopherol) are considered to be 
helpful in the assessment of gastrointestinal absorption and nutritional status in CF, 
and therefore analysis of fat-soluble vitamins are performed annually in most CF 
centres like in ours (62).  
Low vitamin A levels are frequent in patients with CF and are associated with 
disturbed dark adaptation, poorer clinical outcome (63), impaired lung function (64) 
and ocular surface changes (65). There are reports which demonstrated vitamin A 
deficiency regardless of exocrine pancreatic function, nutritional status (66), genotype 
(62) or development of lung disease (67).  
Children and young adults with CF may suffer from bone demineralisation, an 
imbalance between bone deposition and resorption (68;69). Concurrent with the 
increased lifespan, up to three-quarters of adult patients with CF have osteopenia or 
osteoporosis (70). Vitamin D deficiency is considered to play an important role in this 
context and is more likely to be found among patients living in northern latitudes.  
The classical symptoms of hypovitaminosis E like haemolytic anaemia and 
neuropathies are rare in CF. Nevertheless, vitamin E is a powerful antioxidant 
protecting against oxidative stress which derives from chronic respiratory 
inflammation. A consequence of vitamin E deficiency is impaired resistance of 
lipoproteins and cell membranes to oxidation (71). A positive correlation between 
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plasma vitamin E levels and FEV1 in patients with CF was recently reported (72). 
This gives raise to the speculation that early administration of vitamin E may have a 
role in the protection of lung tissue against oxidative damage. Recently, Koscik and 
coworkers have shown that prolonged alpha-tocopherol deficiency in infancy is 
associated with lower cognitive performance (73).  
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5. Aims of the thesis 
 
 
1. To assess the impact of lung parenchyma damage (quantified by a HRCT score) 
on resting energy expenditure in patients with CF and correlate these findings with 
FEV1. 
 
2. To examine whether expiratory HRCT scans might add information about the 
degree of mosaic perfusion in patients with CF and whether this modified HRCT 
score correlates with pulmonary function. 
 
3. To assess disease severity as evaluated by the Shwachman-Kulczycki score and 
to correlate these findings with REE and FEV1 in patients with CF. 
 
4. To evaluate FE-1 values and fat-soluble vitamin profiles in patients with CF, and to 
correlate exocrine pancreatic function to fat-soluble vitamin profiles. To assess the 
difference between fat-soluble vitamin profiles in patients with impaired versus patent 
exocrine pancreatic function. To study, if fat-soluble vitamin deficiency at diagnosis is 
effectively treated by vitamin supplementation. 
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6. Material and methods 
 
 
Haukeland University Hospital serves as a regional centre for CF patients in Western 
Norway (950 000 citizen). The regional incidence of CF is approximately 1 in 4500 
live births (2). This cross sectional cohort study was performed between January 
1999 and August 2000 where patients were enrolled consecutively as part of their 
comprehensive assessment. 
 
 
6.1 Patients 
 
In 1999, seventy-one patients with CF have been living in the three counties that form 
the Western region of Norway (Hordaland, Rogaland, Sogn & Fjordane). Adult 
patients enrolled in this study were followed-up at the Department of Pulmonology, 
Haukeland University Hospital. Twenty-one adult patients from this region have been 
followed fully or partly at The National Centre for CF in Oslo according to tradition 
and were not included in this study. Five adult patients attending our hospital refused 
to participate in the study. Sixteen patients younger than six years were excluded 
due to necessity for cooperation under the technical procedures, leaving 29 patients 
as the basis for this thesis (15 females, median age 13 years).  
For paper III, we enrolled our two five year old patients as well, who were able to 
perform indirect calorimetry. For paper IV, we used retrospective data from the 
patient charts at diagnosis and longitudinal data from the annually routine follow-up 
as well in patients below six years.  
 
The CF diagnosis was made by demonstration of repeated elevated sweat chloride 
concentrations and clinical manifestations compatible with the diagnosis in all 
patients (Rosenstein 1998). Our patients were screened for the ∆F508-mutation and 
several other mutations known to occur in our region (del I507, 394delTT, 3659delC, 
4005+2t>c, G542X, G551D, N551D, N1303K, R117C, R117H, R553X, W128X). Nine 
patients were found to be homozygous for ∆F508 (31%); the remaining 20 patients 
did either have ∆F508/other mutation (8 patients), two other mutations (1 patients), 
one (4 patients) or no detectable mutation (7 patients).  
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DNA analysis was unfortunately incomplete in our hospital in 1999/2000. CF patients 
with unidentified mutations are getting re-evaluated these days at The Centre for 
Medical Genetics and Molecular Medicine, Haukeland University Hospital in Bergen. 
A few more mutations have recently been detected among our study patients. We 
decided therefore to actualise the DNA data presented in this chapter, although the 
original data in the papers are slightly different concerning DNA analysis. General 
patient data, characterizing our study population, are shown in table 1.  
 
 
Table 1: General patient data; mean values, SD. Ranges are shown in parentheses.  
 
  N=29  
Age (years)      16 ± 8,5  (6-40)   
Chloride sweat in mmol/L (Eq/L)   101 ± 26 (62-157) 
Body mass index (kg/m2)    17,8 ±3  (12,6-25,8) 
Shwachman-Kulczycki score    75,4 ±15,7 (28-95) 
FVC – forced vital capacity#    95,0 ±21,9 (47-153) 
FEV1 - forced expiratory volume in one second#  81,3 ± 24,1 (25-131) 
 
#in percent of predicted 
 
 
Our patients attend the outpatient department every 2nd- 3rd month or more often 
when needed. Eight patients (28%) have chronic lung infection with Pseudomonas 
aeruginosa, and they are given 12-day courses of intravenous antibiotic treatment 
every 3rd month.  
Twenty-one patients (72%) have been taking pancreatic enzyme supplementation 
and the amount of lipase was between 5000 and 10000 IE per kilogram bodyweight 
per day. All patients had received conventional therapy for CF for at least six months 
and they were in a clinically stable condition. One patient was treated with insulin 
because of CFRDM. Written informed consent was obtained from patients and/or 
their families. The regional ethics committee approved our study protocol.  
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Table 2 categorizes the four parts of our study. Unfortunately, the number of subjects 
varied between the study parts. Coincidentally, HRCT pictures got lost during the 
process, or HRCT scans during expiration were forgotten by the technicians. There 
were some technical problems with the procedures such as insufficient HRCT scan 
quality. 
 
Table 2: Overview of study designs 
 
 Study I Study II Study III Study IV 
Experimental group 20 CF patients 
6-34 years 
17 CF patients 
6-34 years 
28 CF patients 
5-40 years 
35 CF patients 
2-40 years 
Limitation 9/29 missed # 12/29 missed # 3/29 missed # 
2 new recruited 
Study enlarged 
for younger 
patients 
Control group 16 healthy 
controls 
8-33 years 
 16 healthy 
controls 
8-33 years 
 
Pulmonary imaging 
method 
HRCT, scored 
according to 
modified Bhalla* 
CCR 
HRCT, scored 
according to 
modified 
Helbich* 
CCR 
CCR  
Pulmonary function 
test 
FEV1 FEV1 FEV1  
Resting energy 
expenditure 
IC  IC  
Clinical score SK score  SK score  
Assessment of 
maldigestion 
   FE-1 
Assessment of 
malabsorption 
   Fat-soluble 
vitamins 
 
# HRCT pictures got lost, scans during expiration were forgotten, technical problems with the 
procedures and insufficient HRCT scan quality. 
* See description of HRCT under Methods 
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6.2 Methods 
 
 
6.2.1 High-resolution computer tomography (HRCT) 
 
Pulmonary HRCT was performed (HiSpeed CT, General Electrics, Wisconsin, USA) 
using 1-mm-thinn sections and 10-mm intervals during inspiration, followed by 1-mm 
scans at 20-mm intervals during expiration (level and width settings of approximately 
–600/1500). A paediatric radiologist evaluated the HRCT images without knowledge 
of the clinical condition, and classified the findings according to a modified scoring 
system based on Bhalla's and colleagues (25), table 3a. The morphological criteria 
were based on description of localisation and degree of pathological changes. 
According to Bhalla we evaluated bronchiectasis, peribronchial thickening, mucus 
plugging, sacculations, bullae, emphysema and collapse or consolidation. In addition, 
the presence and degree of mosaic perfusion in inspiration was evaluated according 
to Helbich and colleagues (74), table 3b. The score ranges from 0-27 points, where 0 
represents normal lung parenchyma. 
Finally, we evaluated the presence and degree of mosaic perfusion in expiration 
(patchy lung attenuation resulting from regional differences in lung perfusion), table 
3c. Our modified scoring system thus includes eleven items, and the maximum score 
is 29 (paper II). 
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Table 3a: Pulmonary HRCT scoring system for CF according to Bhalla (25) 
 
Category 0 1 2 3 
Severity of 
bronchiectasis 
Absent Mild (luminal diameter slightly 
greater than diameter of 
adjacent vessel) 
Moderate (luminal diameter two 
to three times the diameter of 
the vessel) 
Severe (luminal diameter 
more than three times the 
diameter of the vessel) 
Severity of 
peribronchial wall 
thickening 
Absent Mild (thickening less or equal 
to diameter of adjacent 
vessel) 
Moderate (thickening greater 
than and up to twice the 
diameter of adjacent vessel) 
Severe (thickening more 
than two times the diameter 
of adjacent vessel) 
Extent of 
bronchiectasis 
Absent 1-5 6-9 > 9 
Extent of mucous 
plugging* 
Absent 1-5 6-9 > 9 
Extent of sacculations 
and abscesses* 
Absent 1-5 6-9 > 9 
Generations of 
bronchial divisions 
involved 
(bronchiectasis or 
plugging) 
Absent Up to the fourth generation Up to the fifth generation Up to the sixth generation 
and distal 
Severity of bullae Absent Unilateral (not more than 4) Bilateral (not more than 4) More than 4 
Severity of 
emphysema* 
Absent 1-5 > 5  
Severity of collapse or 
consolidation 
Absent Sub segmental Segmental or lobar  
 
 
Table 3b: Hebich`s modification of Bhalla`s scoring system; adding evaluation of inspiratory mosaic 
perfusion 
Category 0 1 2 3 
Severity of mosaic perfusion 
in inspiration* 
Absent 1-5 > 5  
 
 
Table 3c: Our modification of Bhalla`s scoring system, adding evaluation of both inspiratory and 
expiratory mosaic perfusion 
 
Category 0 1 2 3 
Severity of mosaic perfusion 
in inspiration* 
Absent 1-5 > 5  
Severity of mosaic perfusion 
in expiration* 
Absent 1-5 > 5  
 
* Numbers are the number of bronchopulmonary segments 
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6.2.2 Conventional chest X-ray (CCR) 
 
Conventional chest x-ray was performed the same day as pulmonary HRCT 
(anterior-posterior, 125 kV). The same paediatric radiologist evaluated CCR 
according to the SK score. CCR-assessment was performed without knowledge of 
clinical status or pulmonary HRCT findings. 
 
 
6.2.3 Pulmonary Function Tests (PFT) 
 
Forced vital capacity (FVC) and forced expiratory volume in one second (FEV1) were 
measured by a Vmax 22 spirometer (Sensormedics, Anaheim, USA). The results 
were compared to a standard reference set (75) and expressed as percent of 
predicted value. 
 
 
6.2.4 Shwachman-Kulczycki score (SK score) 
 
The overall clinical condition was evaluated by the Shwachman-Kulczycki score (34), 
table 4. A maximum of 25 points and a minimum of one point are awarded on a five-
point scale to each of the following categories: general activity, physical examination, 
nutritional status and CCR findings. This results in a global score from 4-100, low 
values reflect poor clinical status (severe= 40 and below; moderate= 40-55; mild= 56-
70; good=71-85; excellent=86-100). 
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Table 4: The Shwachman-Kulczycki score: Overall clinical evaluation of patients with CF 
 
Grading Points General 
activity 
Physical 
examination 
Nutrition CCR findings 
Excellent 
(86-100) 
25 Full normal 
activity, plays 
ball, goes to 
school 
Normal; no cough, 
puls and 
respiration normal, 
clear lungs, good 
posture 
Maintains weight 
and height at > 
25th perc., well 
formed stools; 
good muscle 
mass and tone 
Clear lung fields 
Good 
(71-85) 
20 Lacks 
endurance and 
tiers at the end 
of the day; 
good school 
endurance 
Resting pulse and 
respiration normal; 
rare coughing or 
clearing of throat; 
no clubbing, clear 
lungs; minimal 
emphysema 
Weight and 
height approx. 
15th to 20th perc.; 
stools slightly 
abnormal; fair 
muscle tone and 
mass 
Minimal 
accentuation of 
bronchovascular 
markings, early 
emphysema 
Mild 
(56-70) 
15 May rest 
voluntarily 
during the day; 
tires easily after 
exertion; fair 
school 
attendance 
Occasional cough, 
perhaps in 
morning upon 
rising; respiration 
slightly elevated, 
mild emphysema, 
coarse breath 
sounds, rarely 
localized rales 
early clubbing 
Weight and 
height above 3rd 
perc.; stools 
usually abnormal, 
large and poorly 
formed, very little 
if any abdominal 
distension; poor 
muscle tone with 
reduced muscle 
mass 
Mild emphysema 
with patchy 
atelectasis and 
increased 
bronchovascular 
markings 
Moderate 
(41-55) 
10 Home teacher; 
dyspnoeic after 
short work; 
rests a great 
deal 
Frequent cough, 
usually productive, 
chest retraction; 
moderate 
emphysema; may 
have chest 
deformity; rales 
usually present; 
clubbing 2 to 3+ 
Weight and 
height below 3rd 
perc.; poorly 
formed, bulky 
fatty offensive 
stools; flabby 
muscles and 
reduced mass; 
abdominal 
distension mild to 
moderate 
Moderate 
emphysema; 
widespread areas of 
atelectasis with 
superimposed areas 
of infection; minimal 
bronchiectasis 
Severe 
(<40) 
5 Orthopnoeic, 
confined to bed 
or chair 
Severe coughing 
spells, tachypnoea 
with tachycardia 
and extensive 
pulmonary 
changes; may 
show signs of 
right-sided cardiac 
failure, clubbing 3 
to 4+ 
Malnutrition  
marked; large 
protuberant 
abdomen; rectal 
prolapse; large 
foul frequent, fatty 
movements 
Extensive changes 
with pulmonary 
obstructive 
phenomena and 
infective lobular 
atelectasis and 
bronchiectasis 
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6.2.5 Indirect Calorimetry (IC) 
 
We performed standard computerised open-circuit indirect calorimetry (Vmax, Sensor 
Medics, California, USA) after 12 hours fasting, with at least four hours restriction of 
using β-2 inhalative agents. The patients were placed under the canopy hood in a 
relaxed supine position. Respiratory gas exchange was monitored for 10 minutes to 
allow acclimatisation, followed by a subsequent 20-30 minutes measurement period. 
REE was calculated using the abbreviated Weir formula (76) on a steady state 
period. The steady state period was defined by a period of at least 5 consecutive 
minutes where oxygen uptake and ventilation varied by less than 10%, and 
respiratory quotient varied by less than 5%. We also examined 16 healthy subjects (7 
female, median age 12 years, range 8-33 years) with indirect calorimetry in order to 
verify our predicted values of REE. High REE values represent increased 
metabolism.  
 
 
6.2.6 Faecal elastase-1 (FE-1) 
 
FE-1 was measured as part of assessment of the exocrine pancreatic function. FE-1 
was determined with a commercial sandwich ELISA kit (ScheBo Tech GmbH, 
Wettenberg, Germany), which uses two monoclonal antibodies against different 
specific epitopes of human pancreatic elastase. Measurement of the optical density 
was performed with Multiscan EX (Labsystems, Espoo, Finland). Concentrations of 
elastase-1 above 200 µg/g faeces were considered as normal, values between 100-
200 µg/g faeces were reflecting moderate exocrine pancreatic insufficiency, and 
values below 100 µg/g faeces were taken as a sign of severe deficiency.  
 
 
6.2.7 Fat soluble vitamins 
 
Determination of the serum or plasma levels of retinol (vitamin A), 25-hydroxyvitamin 
D, and alpha-tocopherol (vitamin E) are the most frequently used parameters to 
evaluate status of vitamin A, D, and E, and also to assess the gastrointestinal 
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absorption of the vitamins. This method, described by Aksnes (77), is a simple and 
sensitive method for simultaneous determination of these vitamins in 0.5 ml human 
serum or plasma. The vitamins were extracted from serum by methanol/iso-propanol 
(80/20, v/v) and n-hexane. The n-hexane phase was evaporated and injected to a 
reversed-phase (C-18) high-performance liquid chromatography system. Elution was 
performed with methanol/water (85:15, v/v) for 25-hydroxyvitamin D and retinol, and 
after that by methanol/water (98:2, v/v) for alpha-tocopherol. The eluate was 
monitored by a UV detector at 265 nm for detection of the vitamins. Baseline 
separation was obtained for all vitamins, and the system also permitted separate 
determinations of the D2 and D3 forms of 25-hydroxyvitamin D. The limit of detection 
and interassay variation for determination in 0.5 ml serum were 6.0 nmol/L and 6.2% 
for 25-hydroxyvitamin D2, 6 nmol/l and 6.1% for 25-hydroxyvitamin D3, 0.035 μmol/L 
and 5.0% for retinol, and 1.2 μmol/l and 5.5% for alpha-tocopherol.  
Normal range for vitamin A: >200 µg/L, 25-OH vitamin D: 25-130 nmol/L, vitamin E: 
>5 mg/L. 
 
 
6.2.8 Statistical methods 
 
Data analysis was performed using a commercially available software package 
(SPSS). Descriptive statistics included mean, minimum and maximum values, 
standard deviations and median. Differences in REE between healthy subjects and 
CF patients were tested using a Student’s t test. The correlation between HRCT 
score and REE, HRCT score and FEV1 and REE and FEV1 and the correlation 
between SK score and REE were assessed by the Pearson correlation coefficient. 
Partial correlation adjusting for chronic PSA lung infection was used to assess the 
impact of PSA on the HRCT score and REE. Partial correlation adjusting for age was 
used to assess the impact of age on the modified HRCT score and FEV1. Due to 
small number of cases, we firstly decided to limit our adjustment to just one factor, 
and secondly, we agreed not to run a regression analysis. 
Differences in FE-1 between patients with patent or impaired exocrine pancreatic 
function were tested by Student’s t test. The relation between fat-soluble vitamins 
and FE-1 were assessed by the Pearson correlation coefficient. All reported p values 
are two-tailed and a p < 0.05 was considered significant.  
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7. Summary of the papers 
 
 
Paper I: Resting energy expenditure and lung disease in cystic fibrosis 
Dorlochter L, Roksund O, Helgheim V, Rosendahl K, Fluge G.  
J Cyst Fibrosis 2002;1:131-136. 
 
20 patients performed pulmonary high-resolution computed tomography (HRCT) and 
assessment of resting energy expenditure (REE). HRCT was scored using a 
standardised method. 
The mean HRCT score in our study group was 8,4 ranging from 1 to 22 (median 7,5). 
Bronchiectasis was the most frequent finding (17 of 20 patients, 85%). Peribronchial 
thickening was the second most common finding and was found in 15/21 patients 
(75%). Mucus plugging was present in 14 patients (70%). The mean REE value was 
108,4% of predicted vs. 96,5% of predicted of 16 healthy subjects (t= -2,75; 95% CI -
20,7 to -3,1; p= 0.009). There was a significant correlation between HRCT score and 
REE (r=0,661; p= 0.002), HRCT score and FEV1 (r= -0,851; p< 0.001) and REE and 
FEV1 (r= -0,454; p= 0.044). High resting energy expenditure was correlated with high 
HRCT score (extensive lung damage). After adjusting for chronic PSA lung infection, 
the correlation was slightly less, for REE (r= 0,577; p= 0.01) and for FEV1 (r= -0,596; 
p= 0.007), but still significant. These findings confirm a close interaction between 
lung parenchyma damage and elevated REE in people with CF. Therefore, any 
increase in REE should raise suspicion of progress in lung impairment. 
 
 
Paper II: High resolution CT in cystic fibrosis – the contribution of expiratory 
scans.  
Dorlochter L, Nes H, Fluge G, Rosendahl K.  
Eur J Radiol 2003;47:193-198. 
 
To examine whether expiratory HRCT scans could add information about the degree 
of mosaic perfusion in patients with CF, we performed pulmonary HRCT in 17 CF 
patients both in- and expiratory. HRCT was scored by using a standardised method. 
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The mean HRCT score was 8,2 (1-21, median 8). 11 out of 17 patients demonstrated 
a pathological mosaic perfusion in expiration (65%), while only three patients showed 
mosaic perfusion in inspiration (18%). The degree of expiratory mosaic perfusion was 
graded as severe in nine patients and moderate in two. There was a significant 
correlation between our modified HRCT score and lung function as measured by 
FEV1 (r= -0,778; p< 0.001). After adjusting for age, the correlation was almost the 
same (r= -0,735; p= 0.001). Mosaic perfusion in expiration was a common 
pathological HRCT finding in our study group. It is reasonable to believe that mosaic 
perfusion which only occurs during expiration represents a lower degree of pathology 
than mosaic perfusion seen in both in- and expiration. The clinical significance of 
these findings need further evaluation. 
 
 
Paper III: The Shwachman-Kulczycki score and resting energy expenditure in 
cystic fibrosis.  
Dorlochter L, Helgheim V, Roksund OD, Rosendahl K, Fluge G.  
J Cyst Fibrosis 2003;2:148-151. 
 
We aimed to assess disease severity in 28 patients with CF by evaluating the 
Shwachman-Kulczycki (SK) score and to correlate these findings with resting energy 
expenditure (REE). The overall mean SK score for our CF population was 75,3 ± 
15,7 (range 28-95), which means that our CF patients on average have had a good 
general condition. Mean value of REE was 109,1 ± 13,6% of predicted in our CF 
population. In healthy subjects a mean value of 96,5 ± 8,7% of predicted was found, 
which was significantly lower compared to the cases (t= -3,3; 95% CI -20,3 to -5,0; p= 
0.002). There was a close correlation between the SK score and REE (r= -0.576; p= 
0.001), the SK score and FEV1 (r= 0,796; p< 0.001) and REE and FEV1 (r= -0,403; 
p= 0.034). High REE was correlated with a low SK score. After adjusting for chronic 
PSA lung infection, the correlation was slightly less, for REE (r= -0,488; p= 0.01) and 
for FEV1 (r= 0,629; p< 0.001), but still significant.  
In our younger patients (N= 18, age <16 years) the mean SK score was 80,1 ± 11,2 
compared to 66,8 ± 19,5 in patients above 16 years of age (t= 2,3; 95% CI 1,2 to 
25,1; p= 0.03). There was no significant correlation between the SK score and REE 
in our young patients, whereas, a significant correlation of the SK score and FEV1 
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was present in this group (r= 0.656; p= 0.003). Furthermore, we have found a close 
correlation between SK score and pulmonary HRCT, even after adjustment for PSA 
(unpublished data, r= 0,872; p< 0.001). Our results emphasise the clinical value of 
the SK score, which is easy to assess in a clinical setting. 
 
 
Paper IV: Faecal elastase-1 and fat-soluble vitamin profiles in patients with 
cystic fibrosis.  
Dorlochter L, Aksnes L, Fluge G.  
Eur J Nutr. 2002;41:148-152. 
 
To assess maldigestion and malabsorption, we performed 212 consecutive analyses 
of fat-soluble vitamin profiles and 35 analyses of FE-1 in 35 patients with CF. In 
17/35 patients fat-soluble vitamin profiles were also assessed at diagnosis. Mean 
values of FE-1 for all CF patients were 256,9 µg/g faeces (SD 445,2; median 24,1). 
CF patients considered to have maldigestion (N=24) showed a mean value of 19,9 
µg/g faeces (SD 15,8; median 18,7), those without pancreas affection had a mean 
value of 773,9 µg/g faeces (SD 494,4; median 728,9; Z=-4,7; p< 0.001). Vitamin E 
profiles in patients with exocrine pancreatic insufficiency (PI) was low in 5/9 patients 
at diagnosis (median 3,6 mg/L), one of these showed additional vitamin A and D 
deficiency. Two patients with patent exocrine pancreatic function suffered from 
hypovitaminosis at diagnosis (hypovitaminosis D and combined A/E deficiency). 
Supplementation of pancreatic enzymes and vitamins normalized profiles in this 
group at follow-up.  
While on appropriate supplementation, there was almost no difference in fat-soluble 
vitamin profiles regardless pancreatic function. There was no significant correlation 
between exocrine pancreatic function as measured as FE-1 and fat-soluble vitamin 
profiles, neither in patients with impaired nor in those with patent pancreatic function.  
Severe degree of PI was common in our CF patients. Among 17 patients assessed at 
diagnosis, 9 had PI. Low values for vitamin E were found in five out of these. Once 
treated, they became normal. At follow-up, values were mostly in normal range 
regardless pancreatic function. 
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8. General discussion 
 
The main aim of the present study was to improve understanding of the complex 
interaction between energy imbalance and lung damage in CF. Parts of the study 
focused on disease severity both by scoring lung parenchyma damage and by 
evaluation of the patients' overall clinical condition, others on energy expenditure in 
rest as well as parameters of maldigestion and malabsorption. With the recognition of 
the close link between nutritional status and pulmonary function in CF, treatment and 
prevention of malnutrition have become a major focus in the modern therapeutic 
approach of patients with CF (78;79). 
 
 
8.1 Energy imbalance 
 
Chronic energy imbalance (long-lasting catabolism) with its clinical manifestation as 
malnutrition is unfavourable in CF. It deteriorates life quality and is, among other 
factors, responsible for high morbidity and mortality (45). Wasting has shown to be a 
predictor of survival (80). 
In simple terms, energy imbalance results from a discrepancy between energy intake 
and energy needs.  
Energy losses and elevated energy expenditure are reasons for higher energy needs 
in CF, which, unfortunately, is not always compensated by appropriate intake of 
energy. Exocrine pancreatic insufficiency and pulmonary inflammation as well as 
decreased nutrient intake are considered to be crucial factors in the development of 
energy imbalance. Therefore it is of great interest to address parameters which 
directly or indirectly influence energy imbalance in CF. To contribute to better 
understanding in this context, we focused on different topics of energy imbalance in 
the present study. Figure 2 is an attempt to provide a survey of these close 
interactions, placing energy imbalance in the centre. Each factor is dependent on the 
subjects’ current health situation and shows broad variation during course of the 
disease.  
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Figure 2: Interdependent factors that influence energy imbalance in cystic fibrosis 
 
 
 
Evaluation of energy expenditure in rest was one of our study aims, and we found 
distinct elevated values in our CF patients. Furthermore, we found close correlations 
between REE, HRCT score and FEV1. High REE was correlated with high HRCT 
score and low FEV1, which means impaired pulmonary function (extensive lung 
damage). Fried and colleagues found similar results, a strong correlation between 
declining pulmonary function and increased REE. Once FEV1 falls below 75% of 
predicted values, the REE raises dramatically. In well-nourished CF males with well-
preserved lung function there is only little, if any increase in REE (81). However, 
Girardet et al. demonstrated elevated REE in CF infants free of clinical symptoms 
(82). Bowler and colleagues found increased REE in CF patients with mild lung 
involvement as well (83).  
Whether the genotype plays a role in this context, remains unclear. Several studies 
revealed higher REE in patients who are homozygous for ∆F508 (84;85). Recent 
research has not documented any primary defect of energy metabolism in subjects 
with CF (86;87). Those of our patients, who were homozygous for ∆F508, showed 
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higher REE compared to the other patients. However, this difference did not reach 
statistical significance, probably due to low number of individuals.  
Regarding maldigestion, we have experienced FE-1 as a valid tool to discriminate 
between sufficient and insufficient exocrine pancreatic function. As presented by 
Walkowiak and colleagues (88), this method is useful in evaluating exocrine 
pancreatic function over time as well. Because CF patients with patent pancreatic 
function may be at risk of developing pancreatic insufficiency, they might benefit from 
longitudinal FE-1 measurements to detect pancreatic deterioration as early as 
possible. Moreover, there are recent reports that moderate decreased FE-1 values 
may correlate to residual function of the exocrine pancreas (89;90). Pancreatic 
enzyme supplementation is traditionally based on clinical symptoms, as well as 
analysis of faecal fat excretion accompanied by a simultaneous 72-hour fat intake 
record. Whether enzyme supplementation should be based solely on FE-1 
examination, remains to be seen. Lately, Baker and colleagues pointed out, that 
patients with patent exocrine pancreatic function as well should be thoroughly taken 
care of in respect to weight gain and malnutrition. They found indeed, surprisingly 
better growth parameters in patients with PI compared to patients with PS (91;92). 
Fat-soluble vitamin deficiency is common in CF (62). Hypovitaminosis D and K in 
particular, contribute among other factors to the occurrence of bone disease in CF. 
Due to increased lifespan, this is of growing concern. Evidence is accumulating that 
vitamin K also plays an important role in maximising and maintaining bone mineral 
density (70;93;94). Although not implemented in the present study, we have already 
included analysis of vitamin K in a follow-up study of our cohort.  
Vitamins A, D and E given in appropriate dosages, combined with pancreatic 
enzymes, ensured normal profiles in our patients. Officially recommended 
supplementation of vitamin A and D in Norway during infancy and childhood may 
explain why so few patients had vitamin deficiencies at diagnosis. However, due to 
bad compliance, some patients may have reduced levels, and routine serial 
monitoring of fat-soluble vitamins in patients with CF are recommended (62). 
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8.2 Links between energy imbalance and lung damage 
 
As part of the present study, we have evaluated mosaic perfusion both in inspiration 
and expiration by using HRCT. This finding is considered to be an early manifestation 
of CF lung disease. We believe that mosaic perfusion that only occurs during 
expiration, represents a lower degree of pathology than mosaic perfusion seen in 
both in- and expiration. Other studies focused on volumetric HRCT imaging to 
provide structural and functional lung analysis at the same time. These new methods 
generate three-dimensional data sets and they can detect regional CF lung changes 
before changes in global pulmonary function measurements (28;95).  
Several studies have focused on the impact of energy deficit on lung function, and 
correlations have been demonstrated between lean body mass (96), exocrine 
pancreatic function (97) as well as REE and lung function (81). As part of our study 
protocol, we intended to evaluate body composition by bio-electrical impedance 
analysis (BIA) and skin fold measurements. Although scientifically approved earlier 
(98;99), our experience with these methods was rather disappointing. Measurements 
were showing a broad range of variation, both intra- and interpersonal, and we 
therefore decided to exclude this potentially interesting topic from our study. Using 
dual-energy X-ray absorptiometry (DEXA) is the method of choice today but the 
software for paediatric patients was not available at Haukeland University Hospital at 
study time. However, we intend to look at body composition and bone mineral density 
in our CF cohort with DEXA in our follow-up studies.  
 
Figure 3 is a simplified model, which places findings of our study in a larger 
pathophysiological context of the close interactions between energy imbalance and 
lung parenchyma damage in cystic fibrosis.  
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Figure 3: The interactions between energy imbalance and lung parenchyma damage in cystic fibrosis 
 
 
 
Visualizing lung pathology by HRCT improves understanding of this complex disease 
in general, but HRCT scans are promising for clinicians in particular. The condition of 
the lungs is depicted more precisely than by the traditionally performed CCR or PFT. 
Thus HRCT can give raise to change of airway clearance techniques and provides 
the clinician last not least a tool to increase patients’ engagement in times when 
motivation is inappropriate. Scoring of pulmonary HRCT findings gives the 
opportunity to follow single patients over time (27), compare patients of a cohort in a 
cross-sectional manner like in the present study, or to evaluate treatment effects in 
clinical intervention studies (28). Either way, the clinician gets additional information 
regarding the most life-limiting factor in CF, namely lung disease.  
It is rather astonishing, that Shwachman's overall clinical score from 1958 is 
correlating excellently with the pulmonary HRCT score we used in our study 
(r=0,872; p<0,001; data not presented here), as well as it showed good correlation to 
REE and FEV1. Although there are several drawbacks connected to the SK score, it 
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is easy to perform in a clinical setting, gives broad clinical information of the patients’ 
condition and has the opportunity to monitor disease progression. 
There is still no obvious explanation of a causal relationship between the basic 
chloride channel defect and the association between energy imbalance and lung 
function (55). However, there seems to be a distinct interaction between these 
parameters. What are the starters for the destructive circle in CF? Is it the pulmonary 
disease, the imbalance of energy needs and intake, or is it the basic defect itself? 
Either way, it is of major interest to prevent energy imbalance by focusing on energy 
losses and expenditure as well as on aggressive nutritional support. One should be 
highly aware of raised energy needs when dealing with worsening lung function in 
CF. Prevention and early intervention are most successful in combating nutritional 
failure. 
 
 
8.3 General considerations 
 
Due to necessity for cooperation under the technical procedures, we have based this 
thesis on the investigation of CF patients older than six years (N=29), which accounts 
for approximately 13% (29/215) of all Norwegian CF patients at this age. We consider 
our group as representative in terms of pancreatic function, disease severity, 
treatment options and follow-up, as all Norwegian CF patients follow common 
national guidelines. However, our cohort is just a minor part of the Norwegian CF 
cohort, and therefore we must be careful not to generalize from our findings.  
Moreover, the percentage of identified CF mutations in our cohort is rather low. As 
described earlier, DNA analysis in our hospital in 1999/2000 was incomplete and it is 
still topic of ongoing work. In the meantime, a few more mutations have been 
detected, resulting at present time in 18/29 patients with identified mutations (62%). 
In all other cases, the combination of clinical manifestations and abnormal sweat 
chloride concentrations was the basis for the CF diagnosis.  
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Some Norwegian peculiarities have to be addressed when discussing our study in a 
larger context.  
There might be a difference regarding nutritional habits in Norwegian CF patients 
compared to patients from other countries. Official nutritional guidelines in Norway 
advice vitamin A and D supplementation from four weeks of age and throughout 
childhood, because of the northern climate and limited exposure to sunlight during 
the winter months. Our patients having PI are advised to take a double dose of a 
multivitamin preparation daily, and all patients take vitamin E daily. The doses are 
adjusted according to monitoring of blood levels of the fat soluble vitamins D, A, and 
E. Daily intake of cod liver oil has been encouraged. The recommended five millilitres 
of cod liver oil contain 1200mg omega-3 fatty acids, including 600mg DHA and 
400mg EPA in addition to vitamin A, D3 and E. 52% of our patients take cod liver oil 
daily.  
Secondly, Norwegian people have traditionally a high consumption of fish and fish 
products, especially people living along the coastline, where Bergen is located. 
According to Fluge and colleagues (100), average fish consumption in Norwegian 
young adults has been 270g a week, and more than half of our patients (15/29) were 
eating a fishmeal at least once a week.  
CF patients in Norway seem to run a more favourable course than in many other 
countries. The prevalence of chronic PSA lung infection in Norway is 35 per cent 
(101), and in the patients cohort from western Norway presented here the prevalence 
is 28%, which is rather low, compared to Denmark (45%) (102) or the USA (60%) 
(103). 
Finally, mutations in Norwegian CF patients are not fully revealed yet. One mutation 
described at the Department of Medical Genetics in our hospital (4005+2T>C, Helge 
Boman, personal communication) has not been found in CF patients outside Norway. 
This mutation seems to protect against exocrine pancreatic insufficiency, even when 
occurring together with the ΔF508 mutation. There might well be other mutations 
protecting against exocrine pancreatic insufficiency and carrying a better prognosis 
than usually among CF patients elsewhere.  
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9.  Main conclusions 
 
We found a close interaction between lung damage and elevated REE in our patients 
with CF. Prevention of a negative energy balance is an integral part of the 
surveillance of patients with CF. One should be aware of progress in lung impairment 
when increased REE is found and secondly, deterioration of pulmonary function 
raises the energy needs even more. 
 
Mosaic perfusion in expiratory HRCT scans was a common finding in our study 
group. Our modified HRCT score correlated well with lung function measured by 
FEV1. It is reasonable to believe that mosaic perfusion, only occurring during 
expiration, represents a lower degree of pathology than mosaic perfusion seen in 
both in- and expiration.  
 
The use of the SK score in evaluation of overall disease severity and progression in 
CF is still valid, especially in older patients. Our results emphasise the clinical value 
of the SK score, which is easy to assess in a clinical setting in contrast to many other 
methods.  
 
Severe degree of exocrine pancreatic insufficiency is common in patients with CF. 
There was no correlation of FE-1 levels to fat-soluble vitamin status. Fat-soluble 
vitamins (A, D, E) given in appropriate dosages combined with pancreatic enzymes 
ensured normal profiles in our patients with CF. Officially recommended 
supplementation of vitamin A and D in Norway during infancy and childhood may 
explain why so few patients had vitamin deficiencies at diagnosis. Because CF 
patients with patent pancreatic function may be at risk of developing PI, they might 
benefit from FE-1 measurements as part of longitudinal follow-up to detect pancreatic 
deterioration as early as possible.  
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